- ClinicalTrials.gov ID: NCT03881696
- Recruiting participants (Starts Jul. 31, 2019)
- Not accepting healthy volunteers
- UTSW Principal Investigator: JOHN ANDREW BIRD
summary
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults OUtMATCH.
objective
The primary objective is to compare the ability to consume foods without dose-limiting symptoms during a double-blind placebo-controlled food challenge (DBPCFC) after treatment with either omalizumab or placebo for omalizumab.